Collegium Pharmaceutical Correlations
COLL Stock | USD 30.15 0.41 1.34% |
The current 90-days correlation between Collegium Pharmaceutical and Phibro Animal Health is 0.19 (i.e., Average diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collegium Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collegium Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Collegium Pharmaceutical Correlation With Market
Average diversification
The correlation between Collegium Pharmaceutical and DJI is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Collegium Pharmaceutical and DJI in the same portfolio, assuming nothing else is changed.
Collegium |
Moving against Collegium Stock
0.55 | GILD | Gilead Sciences Potential Growth | PairCorr |
0.48 | LLY | Eli Lilly | PairCorr |
0.48 | OCX | OncoCyte Corp | PairCorr |
0.43 | AZN | AstraZeneca PLC ADR | PairCorr |
0.39 | GOSS | Gossamer Bio | PairCorr |
0.36 | AMGN | Amgen Inc | PairCorr |
0.33 | DRMAW | Dermata Therapeutics | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Collegium Stock performing well and Collegium Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Collegium Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
PAHC | 2.16 | (0.01) | 0.00 | (0.01) | 2.96 | 3.84 | 17.81 | |||
ANIP | 1.65 | 0.28 | 0.14 | 0.24 | 1.77 | 3.04 | 18.94 | |||
PROC | 6.87 | (0.32) | 0.00 | (1.83) | 0.00 | 13.54 | 96.00 | |||
SSIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
AMPH | 1.59 | (0.54) | 0.00 | (1.18) | 0.00 | 3.23 | 14.01 | |||
EGRX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
ALKS | 1.36 | 0.15 | 0.11 | 0.31 | 1.31 | 3.78 | 10.24 | |||
EOLS | 2.94 | 0.17 | 0.05 | 0.08 | 2.90 | 5.47 | 35.35 | |||
PBH | 1.31 | 0.10 | 0.07 | 0.15 | 1.36 | 2.22 | 17.56 | |||
RGC | 12.70 | 5.81 | 0.75 | (0.70) | 5.57 | 46.25 | 265.55 |
Collegium Pharmaceutical Corporate Management
Shirley JD | General VP | Profile | |
Bart Dunn | Executive Development | Profile | |
Scott Sudduth | Head Operations | Profile | |
Christopher MD | Vice Relations | Profile | |
Marlo Manning | Head HR | Profile |